Press

MenaquinGold Receives FDA "No Question" Letter
Synergia Life Sciences has received an FDA “No Question” letter in response to a GRAS Notification for the intended use of the MenaquinGold brand of vitamin K2 MK-7, according to a press release. “Intended use,” in this case, is as a food ingredient and as a nutrient in supplements or foods for special dietary uses intended for children 1 to 13 years old.
Read More...
 
Synergia Life Sciences Receives European Patent for Vitamin K Analogues and Derivatives
Synergia Life Sciences, an ingredients manufacturer based in India, recently received a European patent for its vitamin K2 as menaquinone-7 (MK-7) ingredient, MenaquinGold, for a number of positive effects on cardiovascular health.
Read More...
 
Vitamin K2 may be beneficial for athletic training
Supplements of vitamin K2 may boost the output of the heart by 12% in aerobically trained males and female athletes, says a new study.
Read More...
 
Pharma grade Vitamin K enters supplement market
Viridis BioPharma / Synergia Life Sciences has announced a 10-fold expansion of its vitamin K production facility, a move which sees the company's pharmaceutical-grade ingredient's availability extended to all dietary supplements.
Read More...
 

VISIT OUR
CORPORATE
WEBSITE
FOR MORE
INFORMATION

HERE